If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Basaglar ® (insulin glargine) injection
100 units/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How are patients transitioned from insulin degludec to Basaglar® (insulin glargine)?
Basaglar has not been studied in patients previously on insulin degludec. Therefore, if transitioning from insulin degludec to Basaglar, a different dose of Basaglar and concomitant antihyperglycemic therapies may be needed.
Transitioning From Insulin Degludec to Basaglar
Basaglar® (insulin glargine) 100 units/mL has not been studied in patients previously on insulin degludec.
Dose Comparison Between Insulin Glargine and Insulin Degludec
Based on patient-level meta-analyses that were performed on 7 phase 3a trials that compared insulin degludec with insulin glargine (), a transition from insulin degludec to Basaglar may be made on a unit-to-unit basis. The dose of Basaglar may require up titration for
- basal-bolus-treated patients with type 1 diabetes, and
- insulin-naive patients with type 2 diabetes.1
Category |
Insulin Glargine |
Insulin Degludec |
Dose Difference |
P Value |
T1DB/B |
0.77 units/kg |
0.68 units/kg |
12% |
<.0001 |
T2Dinsulin-naive |
0.43 units/kg |
0.39 units/kg |
10% |
.0004 |
T2DB/B |
1.18 units/kg |
1.22 units/kg |
0% |
NS |
Abbreviations: NS = not significant; T1DB/B = basal-bolus-treated patients with type 1 diabetes; T2DB/B = basal-bolus-treated patients with type 2 diabetes; T2Dinsulin-naïve = insulin-naive patients with type 2 diabetes.
General Dosing Guidelines When Transitioning to Basaglar
If transitioning from a treatment regimen with an intermediate- or long-acting insulin to a regimen with Basaglar, a change in the dose of the basal insulin may be required.2
Patients may be predisposed to hypoglycemia or hyperglycemia by changes in insulin
- strength
- manufacturer
- type
- injection site, or
- method of administration.2
Insulin treatment changes should be made
- under close medical supervision, and
- with increased frequency of blood glucose monitoring.2
In patients with type 2 diabetes, dosage adjustments of concomitant antihyperglycemic medications may be needed.2
Enclosed Prescribing Information
References
The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).
1Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther. 2014;5(2):435-446. http://dx.doi.org/10.1007/s13300-014-0076-9
2Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
Date of Last Review: October 10, 2022